New Settings for Immune Checkpoint Inhibitors in Urothelial Bladder Cancer
With many new indications for immune checkpoint inhibitors in urothelial bladder cancer, as well as a number of important ongoing trials using these agents, timely education on this topic is important.
  • Bladder Cancer
  • Recorded Webcast
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation